alzheimer

Documents about alzheimer

• Bumetanide in Patients With Alzheimer's Disease#394657ClinicalTrials.gov
• AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)#184947ClinicalTrials.gov
• Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine#287395ClinicalTrials.gov
• Systematic Multi-domain Alzheimer's Risk Reduction Trial#398239ClinicalTrials.gov
• Sociodemographic determinants of Alzheimer’s disease in primary care: evidence from the province of Salamanca (Spain)#283951Gestión del Repositorio Documental de la Universidad de Salamanca
• Nasal Protollin in Early Symptomatic Alzheimer's Disease#390964ClinicalTrials.gov
• Analyzing single nuclei transcriptomes of Alzheimer's disease mice model#261747edoc-Server
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease#6831OpenAlex
• Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease#7394OpenAlex
• ADVANCE Study: Alzheimer Disease eVAluation iN Clinical PracticE#249732ClinicalTrials.gov
• Farming exposures and Alzheimer's disease: cross-sectional analysis within the French AGRICAN cohort#202472HAL (France)
• Dementia and Alzheimer's Disease: An Overview#167570Digital Commons @ University of Georgia School of Law
• Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease#387271ClinicalTrials.gov
• Identification de facteurs de risque génétique liés au sexe pour la maladie d'Alzheimer#14158HAL (France)
• Altered resting-state functional connectivity in individuals at risk for Alzheimer’s disease: a longitudinal study#329704Dipòsit Digital de la Universitat de Barcelona
• Situación actual de los indicadores de mortalidad por Alzheimer en Castilla y León#438757Gestión del Repositorio Documental de la Universidad de Salamanca
• Clinical diagnosis of Alzheimer's disease#6815OpenAlex
• Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's#158073ClinicalTrials.gov
• Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers#391041ClinicalTrials.gov
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)#28528ClinicalTrials.gov
• 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease#28413ClinicalTrials.gov
• Physical activity and Alzheimer’s disease: a call for evidence incorporation#126826HAL (France)
• A distinct tau oligomer strain defines the molecular and proteomic landscape of rapidly progressive Alzheimer’s disease#398839HAL (France)
• Proteomic comparison of hippocampal neurofibrillary tangles in PART, intermediate Alzheimer's disease and advanced Alzheimer's disease.#425058NCBI PubMed Central
• Entre el silenci dels records: recerca d’una memòria perduda. Nous enfocaments terapèutics en la malaltia de l’Alzheimer#185002Dipòsit Digital de la Universitat de Barcelona
• Lifestyle factors and plasma biomarkers of Alzheimer's disease: A narrative review#179402HAL (France)
• The use of memantine for prevention of Alzheimer's disease: Pilot feasibility study rationale and protocol#217710Europe PMC
• The use of memantine for prevention of Alzheimer's disease: Pilot feasibility study rationale and protocol#231262Europe PMC
• Estratégias de enfrentamento utilizadas por cuidadores familiares de pessoas idosas com Alzheimer: revisão integrativa#289186Repositório Institucional da Universidade Federal de Mato Grosso do Sul
• Influencia del Trabajo de Enfermería en Adultos Mayores con Alzheimer#406754Repositorio de la Pontificia Universidad Católica del Ecuador
• PATIENT DERIVED-INDUCED PLURIPOTENT STEM CELL MODEL OF ALZHEIMER'S DISEASE REVEALS DYSREGULATED ANGIOGENESIS AND EARLY CELLULAR SENESCENCE IN HUMAN ENDOTHELIA#288521ScholarBank@NUS
• Astrocytes, via RTP801, contribute to cognitive decline by disrupting GABAergic-regulated connectivity and driving neuroinflammation in an Alzheimer's disease mouse model#184965Dipòsit Digital de la Universitat de Barcelona
• No room of one’s own: Essays on caregiving and alzheimer's disease#234205Animo Repository
• Four decades of Alzheimer's disease discoveries, data, and research resources: The NIH Alzheimer's Disease Research Center Program.#265496NCBI PubMed Central
• Methionine, Homocysteine, and Methylation Levels Predict Cognitive Decline in Alzheimer's Disease#266536Europe PMC
• White matter hyperintensities in Alzheimer's disease: Beyond vascular contribution#347655HAL (France)
• “Las formas de olvido y las formas de memoria: los múltiples sentidos en una dinámica familiar que gira en torno al Alzheimer”,#188251Repositorio Institucional Javeriano
• NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease#7359OpenAlex
• Engineering nanobodies for drug delivery systems in Alzheimer's disease.#9730PubMed
• Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study#126052ClinicalTrials.gov
• Risk Reduction for Alzheimer's Disease#195454ClinicalTrials.gov
• Glial Cells in Behavioral and Psychological Symptoms of Alzheimer’s Disease#231276Europe PMC
• Psychopathologie de la maladie d'Alzheimer : une approche clinique de la mémoire démentielle#235293HAL (France)
• Intersection Of Capacity Law And Neurodegenerative Disease With A Focus On Alzheimer’s Medication#401534EliScholar
• Amyloid‐related imaging abnormalities (ARIA) in anti‐amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup#125786Europe PMC
• Tau oligomerization induces nuclear lamina invagination and chromatin remodeling in Alzheimer's disease#127562Europe PMC
• Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics#161197HAL (France)
• Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease#175037ClinicalTrials.gov
• Studying the interaction between Polyoxometalates and Amyloid peptides in the context of Alzheimer’s disease#195713HAL (France)
• Bayesian modelling demonstrates clinically relevant heterogeneity in Tau PET patterns in Alzheimer's disease#235003Europe PMC